
    
      This clinical investigation is a prospective, randomized, double-blinded, placebo-controlled
      study of advanced heart failure patients treated with the HM3 with two different
      antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with
      placebo.
    
  